A citation-based method for searching scientific literature

Yunpeng Yang, Jianya Zhou, Jianying Zhou, Jifeng Feng, Wu Zhuang, Jianhua Chen, Jun Zhao, Wei Zhong, Yanqiu Zhao, Yiping Zhang, Yong Song, Yi Hu, Zhuang Yu, Youling Gong, Yuan Chen, Feng Ye, Shucai Zhang, Lejie Cao, Yun Fan, Gang Wu, Yubiao Guo, Chengzhi Zhou, Kewei Ma, Jian Fang, Weineng Feng, Yunpeng Liu, Zhendong Zheng, Gaofeng Li, Ning Wu, Wei Song, Xiaoqing Liu, Shijun Zhao, Lieming Ding, Li Mao, Giovanni Selvaggi, Xiaobin Yuan, Yuanqing Fu, Tao Wang, Shanshan Xiao, Li Zhang. Lancet Respir Med 2020
Times Cited: 64



Lucio Crinò, Myung-Ju Ahn, Filippo De Marinis, Harry J M Groen, Heather Wakelee, Toyoaki Hida, Tony Mok, David Spigel, Enriqueta Felip, Makoto Nishio, Giorgio Scagliotti, Fabrice Branle, Chetachi Emeremni, Massimiliano Quadrigli, Jie Zhang, Alice T Shaw. J Clin Oncol 2016
Times Cited: 245




List of shared articles



Times cited

Decoding the Evolutionary Response to Ensartinib in Patients With ALK-Positive NSCLC by Dynamic Circulating Tumor DNA Sequencing.
Yunpeng Yang, Jie Huang, Tao Wang, Jianya Zhou, Jing Zheng, Jifeng Feng, Wu Zhuang, Jianhua Chen, Jun Zhao, Wei Zhong,[...]. J Thorac Oncol 2021
12

[Pharmacology and Clinical Evaluation of Ensartinib Hydrochloride Capsule].
Yang Wang, Xiaobin Yuan, Jiayan Xiong, Zhidong Hao, Xingzhe Peng, Wanlin Chen, Lingling Cui, Hua Li, Xiulan Wang, Xiangbo He,[...]. Zhongguo Fei Ai Za Zhi 2020
2

Targeting ALK Rearrangements in NSCLC: Current State of the Art.
Ling Peng, Liping Zhu, Yilan Sun, Justin Stebbing, Giovanni Selvaggi, Yongchang Zhang, Zhentao Yu. Front Oncol 2022
3


Pharmacotherapeutic advances with anaplastic lymphoma kinase inhibitors for the treatment of non-small cell lung cancer.
Alice Indini, Erika Rijavec, Michele Ghidini, Claudia Bareggi, Donatella Gambini, Barbara Galassi, Paola Antonelli, Giulia Bettio, Clarissa Di Nubila, Francesco Grossi. Expert Opin Pharmacother 2020
6

Treatment Sequencing for Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer.
Diego Kauffmann-Guerrero, Kathrin Kahnert, Rudolf M Huber. Drugs 2021
6

Overcoming TKI resistance in fusion-driven NSCLC: new generation inhibitors and rationale for combination strategies.
Alessandro Russo, Andrés F Cardona, Christian Caglevic, Paolo Manca, Alejandro Ruiz-Patiño, Oscar Arrieta, Christian Rolfo. Transl Lung Cancer Res 2020
6


Emerging Systemic Treatment Perspectives on Brain Metastases: Moving Toward a Better Outlook for Patients.
Christopher Alvarez-Breckenridge, Jordi Remon, Yolanda Piña, Edwin Nieblas-Bedolla, Peter Forsyth, Lizza Hendriks, Priscilla K Brastianos. Am Soc Clin Oncol Educ Book 2022
2

Systematic Review and Network Meta-Analysis of Anaplastic Lymphoma Kinase (ALK) Inhibitors for Treatment-Naïve ALK-Positive Lung Cancer.
Cheng-Hao Chuang, Hsiao-Ling Chen, Hsiu-Mei Chang, Yu-Chen Tsai, Kuan-Li Wu, I-Hua Chen, Kung-Chao Chen, Jui-Ying Lee, Yong-Chieh Chang, Chin-Ling Chen,[...]. Cancers (Basel) 2021
16


[Recommendations from Experts in the Management of Adverse Reactions 
to ALK Inhibitors (2021 Version)].
Ke Wang, Juan Li, Jianguo Sun, Li Li, Xi Zhang, Jianyong Zhang, Min Yu, Xianwei Ye, Ming Zhang, Yu Zhang,[...]. Zhongguo Fei Ai Za Zhi 2021
1

The Emerging Therapeutic Landscape of ALK Inhibitors in Non-Small Cell Lung Cancer.
Valerio Gristina, Maria La Mantia, Federica Iacono, Antonio Galvano, Antonio Russo, Viviana Bazan. Pharmaceuticals (Basel) 2020
29